As Action on Senate Finance Committee Drug Pricing Bill Set to Resume, National LTC Pharmacy Advocacy Group Praises Cap on Patient Costs
Commenting on several elements of the Senate Finance Committee’s pending drug pricing bill, the Senior Care Pharmacy Coalition (SCPC) praised the broad contours of the sweeping legislation and offered strong support for the proposed cap on Medicare Part D beneficiaries’ out-of-pocket costs…Read More
How Medical Middlemen Delay and Deny Cancer Treatments to Americans
Morning Consult BY TED OKON August 21, 2019 Democratic presidential candidates have devoted plenty of debate time to health care and pointed fingers at a familiar bogeyman: the all-powerful pharmaceutical industry. They are right to be outraged at high drug prices and the affordability crisis millions of Americans face every day, but they missed a huge problem read more…
Senate bill aims to protect taxpayers from costly drugs
Roll Call One proposed change to Medicare prescription drug benefit is to help the program control costs it absorbs to keep premiums stable. (CQ Roll Call file photo) Congress this year could enact the biggest overhaul of Medicare’s prescription drug benefit since it was first established in 2003. If successful, seniors — and taxpayers — read more…
Senate committee unveils ambitious plan to cap drug price hikes, out-of-pocket expenses
Stat News By LEV FACHER and NICHOLAS FLORKO JULY 23, 2019 WASHINGTON — A key Senate committee on Tuesday unveiled a long-awaited package of drug pricing reforms that would cap how much drug makers can hike their prices in Medicare. It would also cap out-of-pocket expenses for Medicare beneficiaries and dramatically reform the program’s prescription drug benefit.The bipartisan effort, read more…
Generic drugs ‘wildly overpriced’ in Medicare, study finds
Becker’s Hospital Review Morgan Haefner – Monday, July 15th, 2019 Many generic drugs in Medicare Part D are “wildly overpriced,” according to an analysis from drug pricing research firm 46brooklyn. The report, which examined data from CMS’ Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files, found that while some generic drugs are priced fairly, others “show unbelievable read more…
National LTC Pharmacy Advocacy Group Asks CMS to Release “Summary Data” on PBM Medicare Spread Pricing Activity
SCPC Thanks CMS for Curtailing PBM Medicaid Spread Pricing; Time for Similar Medicare Transparency…Read More.
‘An Arm And A Leg’: Why Are Drug Prices So Random? Meet Mr. PBM
Kaiser Health News
Surely, an old-time, generic drug can’t cost $720 — for a three-month supply…Read More.
As CMS Mitigates Medicaid ‘Spread Pricing’ Abuse, Time to Address Medicare Abuses
Under the leadership of Centers for Medicare and Medicaid Services Administrator Seema Verma, the Trump administration recently released key guidance mitigating pharmacy benefit managers’ abusive “spread pricing” practices in state Medicaid-managed care programs…Read More.
Drug middlemen name own prices, methodology goes unchallenged
The Columbus Dispatch
Ohio Medicaid officials and their managed-care contractors say they’re bringing new transparency to an opaque drug-delivery system that in 2017 saw more than a quarter-billion-dollar markup to taxpayers…Read More.